Gastric Bypass (RYGB)

At a Glance

• What it is: A small stomach pouch is connected directly to the small intestine, bypassing most of the stomach and the duodenum
• Who it is for: Recommended by the 2022 ASMBS/IFSO guidelines for adults with a BMI of 35 or higher, and considered at a BMI of 30–34.9 with metabolic disease (27.5 or higher for people of Asian descent) (Eisenberg et al., Surgery for Obesity and Related Diseases, 2022). It is the preferred operation for most patients with significant reflux
• Results: The most studied bariatric operation, with strong long-term results for weight, diabetes and reflux in randomized trials (see Landmark Evidence below)
• Main trade-off: Lifelong vitamins, and small risks of marginal ulcer and internal hernia
• Hospital stay and recovery: Usually one night; most return to desk work in one to two weeks

Roux-en-Y gastric bypass is widely regarded as the gold standard of weight-loss surgery and remains one of the two most commonly performed bariatric operations worldwide, alongside sleeve gastrectomy. Unlike a purely restrictive operation, RYGB works through three mechanisms at once — restriction, altered nutrient absorption, and favorable changes in gut hormones that increase satiety and suppress hunger. A small (roughly 30 mL) stomach pouch is created and connected directly to the small intestine, bypassing the remainder of the stomach, the duodenum, and the upper jejunum (Takla, JOMI, 2024; Barbat and Nimeri, Handbook of Metabolic and Bariatric Surgery, 2022).

RYGB has more than six decades of track record and the deepest long-term evidence base of any metabolic procedure, with durable weight loss and metabolic improvement documented out to 15–20 years (Pina et al., Surgical Endoscopy, 2026; McClelland et al., Surgical Endoscopy, 2023). It is a particularly strong choice for patients who also suffer from type 2 diabetes or significant acid reflux, and it is frequently selected as the destination operation when converting a prior sleeve gastrectomy or adjustable gastric band that has produced inadequate weight loss or reflux (Misra et al., Obesity Surgery, 2020; Noel et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2026). For patients weighing RYGB against the sleeve, SADI-S, or duodenal switch, procedure selection is individualized to body-mass index, metabolic disease, and reflux status.

‍

Patients considering bypass with Dr. de la Cruz-Muñoz can read about the local program, hospital stay and recovery timeline on Gastric Bypass Surgery in Miami, FL.

RYGB produces weight loss and metabolic improvement through three combined effects. First, the small gastric pouch restricts the volume of food that can be eaten at one time. Second, rerouting the food stream past the upper intestine changes how and where nutrients are absorbed and mixed with digestive enzymes. Third — and most importantly for its metabolic power — bypassing the duodenum and proximal jejunum triggers changes in gut hormones (including enhanced satiety and suppressed hunger signaling) that drive appetite reduction and rapid improvement in blood sugar control, often before significant weight is even lost (Apovian et al., Clinical Management of Obesity, The Obesity Society, 2025; Acosta et al., Clinical Gastroenterology and Hepatology, 2017; Barbat and Nimeri, Handbook of Metabolic and Bariatric Surgery, 2022).

This hormonal, or "incretin," effect is what distinguishes gastric bypass from restriction-only procedures and underlies its leading role in metabolic surgery for diabetes. It is also why RYGB remains a reference operation even as GLP-1 medications expand the nonsurgical treatment landscape.

‍

• Durable, substantial weight loss — peak total body weight loss near 32% at roughly 18 months, maintained at approximately 23–25% beyond 10–20 years (Pina et al., Surgical Endoscopy, 2026; McClelland et al., Surgical Endoscopy, 2023).

• Powerful diabetes control — high rates of type 2 diabetes remission, superior to medical therapy and to restrictive-only operations such as the sleeve (Barbat and Nimeri, Handbook of Metabolic and Bariatric Surgery, 2022; Shubeck et al., JAMA, 2018).

• Reflux relief — RYGB is the bariatric operation of choice for patients with GERD, erosive esophagitis, or Barrett's esophagus. (Misra et al., Obesity Surgery, 2020; Drai et al., Obesity Surgery, 2023).

• Broad comorbidity improvement — sustained reductions in hypertension, dyslipidemia, and obesity-related disease burden (Barbat and Nimeri, Handbook of Metabolic and Bariatric Surgery, 2022; Shubeck et al., JAMA, 2018).

• Proven long-term safety — perioperative mortality of 0.03%–0.2%, comparable to routine elective surgery such as cholecystectomy or hip replacement (Arterburn et al., JAMA, 2020; Aaron et al., Gastrointestinal Surgical Emergencies, 2021).

‍

RYGB is generally offered to adults with a BMI ≥ 35 kg/m² with obesity-related comorbidities, who have not achieved durable results with nonsurgical measures (Mingrone et al., Lancet Diabetes & Endocrinology, 2018; Mechanick et al., Obesity, 2020). Under contemporary society criteria, selected patients with a BMI of 30–34.9 kg/m² and metabolic disease — particularly inadequately controlled type 2 diabetes — are also appropriate candidates.

It is often the preferred procedure in patients with metabolic syndrome, or significant GERD, hiatal hernia, or Barrett's esophagus, where a sleeve gastrectomy would be less suitable (Misra et al., Obesity Surgery, 2020; Drai et al., Obesity Surgery, 2023). Candidacy is confirmed through multidisciplinary evaluation including nutritional, medical, and behavioral assessment. Patients unsure whether RYGB, sleeve gastrectomy, SADI-S, or an endoscopic option such as ESG or a gastric balloon best fits their goals are evaluated individually.

‍

‍

‍

RYGB is performed minimally invasively — laparoscopically or robotically — under general anesthesia, typically with a one- to two-night hospital stay (Takla, JOMI, 2024; Arterburn et al., JAMA, 2020). The three core technical steps are: (1) construction of a small (≤ 30 mL) gastric pouch based on the lesser curvature using a linear stapler; (2) creation of the Roux (alimentary) limb by dividing the jejunum and bringing the distal segment up to the pouch; and (3) a gastrojejunal anastomosis plus a downstream jejunojejunal anastomosis that restores intestinal continuity (Kellogg and Ghanem, Yamada's Textbook of Gastroenterology, 2022).

Roux limb lengths are typically 100–150 cm and biliopancreatic limbs 40–75 cm, and mesenteric defects are closed to reduce the risk of later internal hernia (Aaron et al., Gastrointestinal Surgical Emergencies, 2021; Abedalqader et al., Obesity Surgery, 2025). A concurrent hiatal hernia, if present, is repaired at the same operation, which is one reason RYGB pairs so well with reflux-directed care.

‍

‍

‍

Early complications (within 30 days) can include anastomotic leak, bleeding, bowel obstruction, venous thromboembolism, internal hernia, and wound infection (Arterburn et al., JAMA, 2020; Aaron et al., Gastrointestinal Surgical Emergencies, 2021).

Late complications (after 30 days) include marginal ulceration, anastomotic stricture, internal hernia, bowel obstruction, dumping syndrome, gallstones, incisional hernia, and nutritional/vitamin deficiencies requiring lifelong supplementation (Noel et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2026; Gribsholt et al., JAMA Surgery, 2016).

Thirty-day mortality is under 0.5%, and overall perioperative mortality ranges 0.03%–0.2% (Arterburn et al., JAMA, 2020). Internal herniation is the most significant late cause of reoperation. Gallstones develop in a notable minority (roughly 7–28%) — a reason some patients ultimately require cholecystectomy — and iron-deficiency anemia (predominantly in women) and marginal ulcers are the most common late medical issues, both highly manageable with monitoring and treatment (Gaete et al., Obesity Surgery, 2024; Gribsholt et al., JAMA Surgery, 2016).

‍

‍

‍

Most patients go home within one to two days and follow an enhanced-recovery (ERABS) pathway emphasizing early mobilization, multimodal opioid-sparing analgesia, and early oral hydration (Díaz-Vico et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2022). Clear liquids begin the night of surgery, advancing to full liquids by postoperative day one. A staged diet progression (liquids → pureed → soft → solids) unfolds over approximately 4–6 weeks under dietitian guidance (Mechanick et al., Obesity, 2020). Many patients return to desk work within 1–2 weeks, with full activity restored over several weeks.

‍

‍

‍

RYGB offers the longest and most consistent long-term data of any metabolic operation. Weight loss peaks around 18–24 months and stabilizes at roughly 23–27% total body weight loss maintained out to 15–20 years (Pina et al., Surgical Endoscopy, 2026; Barberá-Carbonell et al., Obesity Surgery, 2025). At 7 years, mean weight loss is approximately 28% with minimal regain between years 3 and 7 (McClelland et al., Surgical Endoscopy, 2023).

Comorbidity improvements — particularly in diabetes, hypertension, and lipids — are durable, though diabetes remission rates gradually decline over 10–15 years, especially in patients who were insulin-dependent preoperatively (Shubeck et al., JAMA, 2018; Pina et al., Surgical Endoscopy, 2026).

Lifelong follow-up and supplementation are essential to sustaining these gains, and patients who experience significant regain can be supported with medical therapy, GLP-1 medications, or, in selected cases, revisional bariatric surgery (Mingrone et al., Lancet Diabetes & Endocrinology, 2018).

‍

Landmark Evidence

• SM-BOSS (217 patients): excess BMI loss at 5 years was 68.3% after bypass versus 61.1% after sleeve. Reflux resolved in 60% of bypass patients with GERD versus 25% after sleeve, and worsened in 6% versus 32% (Peterli et al., JAMA, 2018). At 10 years, only 5.5% of bypass patients had been converted to another operation, versus 30% after sleeve (JAMA Surgery, 2025).
• SLEEVEPASS (240 patients, 10 years): median excess weight loss was 50.7% after bypass versus 43.5% after sleeve, with better hypertension remission after bypass (Salminen et al., JAMA Surgery, 2022).
• STAMPEDE (5 years): 29% of bypass patients achieved an HbA1c of 6% or less, versus 5% with intensive medical therapy alone (Schauer et al., New England Journal of Medicine, 2017).
• Internal hernia prevention: closing the mesenteric defects cut reoperation for small bowel obstruction from 10.2% to 5.5% in a 2,507-patient randomized trial (Stenberg et al., The Lancet, 2016), and Dr. de la Cruz-Muñoz reported similar findings in his own series (Surgery for Obesity and Related Diseases, 2011).
• Survival: Across 17 studies and more than 174,000 people, metabolic and bariatric surgery was associated with a 49% lower risk of death and a median of 6.1 additional years of life compared with non-surgical care. The benefit was greatest in people with type 2 diabetes (Syn et al., The Lancet, 2021).

How It Compares

• Versus sleeve gastrectomy: somewhat more weight loss, far better for reflux, and fewer later conversions, with a small risk of marginal ulcer and internal hernia.
• Versus OAGB: similar weight loss with less risk of bile reflux and nutritional deficiency.
• Versus duodenal switch: less weight loss at very high BMI but fewer nutritional complications.

More in Bariatric Surgery Procedures

Related procedures: One‑Anastomosis Gastric Bypass, SADI-S, Duodenal Switch, Magnetic Duodeno-Ileal Bypass with Sleeve, Adjustable Gastric Band Surgery, Medical Weight Loss Program. For an overview of all options, see Bariatric Surgery.

Conditions treated: Obesity, Type 2 Diabetes, Sleep Apnea, Metabolic Dysfunction–Associated Steatohepatitis, Metabolic Syndrome, High Blood Pressure.

Roux-en-Y gastric bypass is the most physiologically powerful bariatric and antireflux operation available — and it rewards surgical experience, careful patient selection, and a lifelong management plan more than almost any other procedure. Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM, brings precisely that depth of expertise.

• High-volume, metabolic and bariatric expertise. Gastric bypass has more steps and more technical nuance than the sleeve, and outcomes are consistently better in experienced, high-volume hands. Dr. de la Cruz-Muñoz performs the bypass minimally invasively (laparoscopic and robotic) as a routine, refined operation, including the complex re-operative and conversion cases that other centers refer out. He has performed over 5,000 Roux-en-Y gastric bypasses.

• Board-certified in both surgery and obesity medicine (DABOM). Dual certification means the bypass is treated as the metabolic operation it truly is — leveraging its powerful effects on diabetes, reflux, and the gut hormones that drive hunger — within a comprehensive, chronic-disease plan rather than a one-time procedure.

• Physiology-first patient selection. The bypass is often the best operation for specific patients — those with significant acid reflux or Barrett's esophagus, higher BMI, type 2 diabetes, or severe metabolic disease. Dr. de la Cruz-Muñoz individualizes the recommendation using objective assessment, so patients who would be better served by a bypass than a sleeve are identified up front, and vice versa.

• The right operation, not just an available one. Because he offers the full range of procedures — Roux-en-Y gastric bypass, sleeve gastrectomy, SADI-S, duodenal switch, and revisional/conversion surgery — the recommendation is driven by what is best for you. For many patients the choice is genuinely between a sleeve and a bypass, and that decision is made together, based on your anatomy, reflux status, metabolic health, and goals (see the companion sleeve gastrectomy page for that comparison).

• A destination for conversions and salvage. Gastric bypass is frequently the definitive answer for patients with reflux after a sleeve, weight regain after another operation, or a failed antireflux repair. Dr. de la Cruz-Muñoz's combined foregut and metabolic expertise means these complex conversions are managed in experienced hands.

• Multidisciplinary, lifelong follow-up. Durable results after bypass depend on structured aftercare — nutrition, protein and vitamin supplementation (iron, B12, calcium, vitamin D), body-composition monitoring to preserve muscle, and long-term metabolic surveillance. His program is built around a lasting partnership, not a single day in the operating room.

For patients considering gastric bypass, this means an honest evaluation of whether the bypass or the sleeve is the better fit, an expertly performed minimally invasive operation, and a team committed to protecting your health and your results for years to come.

Dr. de la Cruz-Muñoz has been performing bariatric surgery for over 25 years and has completed more than 9,000 bariatric operations — a volume few surgeons reach.

Research and Publications

Dr. de la Cruz-Muñoz's published and presented work on this topic includes:

• de la Cruz-Muñoz N, Messiah SE, Lopez-Mitnik G, et al. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term outcome results. Journal of the American College of Surgeons. 2011;212(4):505–511.
• Iacobellis G, Xu C, Campo R, de la Cruz-Muñoz N. Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass. Obesity Surgery. 2015;25(5).
• de la Cruz-Muñoz N, Cabrera J, Cuesta M, Hartnett S, Rojas R. Closure of mesenteric defect can lead to a decrease in internal hernias after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases. 2011;7(2):176–180.
• de la Cruz-Muñoz N, Messiah S, Cabrera J, et al. Four-year weight outcomes of laparoscopic gastric bypass surgery and adjustable gastric banding among multiethnic adolescents. Surgery for Obesity and Related Diseases. 2010;6(5):542–547.

If you live in South Florida or plan to travel for your operation, our gastric bypass surgery in Miami page explains how the evaluation, surgery day and follow-up visits work at our practice.

Authored by Nestor de la Cruz-Muñoz, MD, FACS, DABOM. Last updated November 2026.

Patients can expect peak total body weight loss of approximately 31–36% at 18–24 months, stabilizing at roughly 23–27% over the long term (Pina et al., Surgical Endoscopy, 2026; Barbat and Nimeri, Handbook of Metabolic and Bariatric Surgery, 2022).

At 5 years, large cohorts report about 24% TWL maintained, and most patients sustain ≥ 25% weight loss through 10–15 years (McClelland et al., Surgical Endoscopy, 2023).

Individual results vary with adherence, biology, and follow-up, and tend to exceed those of restriction-only procedures such as the sleeve.

‍

• Type 2 diabetes: remission in roughly 54–60% of patients at mid-term follow-up, with durable but declining remission (~38% at 15 years) (Surgical Endoscopy, 2026; JAMA, 2018).
• Hypertension: long-term complete remission in roughly 15–42% of patients (Annals of Surgery, 2025; Surgical Endoscopy, 2023).
• Dyslipidemia: sustained improvement and remission (Annals of Surgery, 2025; Surgical Endoscopy, 2020).
• Obstructive sleep apnea: high rates of resolution, with reduced CPAP use (Annals of Surgery, 2025; Surgical Endoscopy, 2023).

‍

Some weight regain is expected; significant regain (≥15% of weight lost) can occur in up to 50% of patients within 5 years (JAMA, 2020). Prevention centers on a tiered, multidisciplinary approach: ongoing dietary and behavioral counseling, protein-focused nutrition, regular physical activity, and — when needed — anti-obesity medications or revisional procedures (Obesity Surgery, 2026; JAMA, 2020).

RYGB is the preferred bariatric operation for patients with significant acid reflux because it reliably improves GERD, in contrast to sleeve gastrectomy, which can worsen reflux (Journal of Laparoendoscopic & Advanced Surgical Techniques, 2020; JAMA, 2020). For this reason, patients with sleeve gastrectomy and severe reflux are frequently converted to RYGB.

For inadequate weight loss or weight regain, options after RYGB include endoscopic transoral outlet reduction (TORe), pouch/anastomosis revision, adding a restrictive ring ("banded bypass"), or distalization (lengthening the bypassed intestine). Surgical revisions produce more durable weight loss than endoscopic approaches but carry higher complication rates (Obesity Reviews, 2023; Obesity Surgery, 2024; Yamada's Textbook of Gastroenterology, 2022).

Preserving lean muscle during rapid weight loss depends on adequate protein intake (typically 80–100 g per day) and resistance/physical activity. A balanced diet with emphasis on protein helps prevent protein deficiency after RYGB (JAMA, 2020).

‍

Nearly all insurers cover RYGB. Most require a BMI of 40 or greater, or 35 or greater with a comorbidity; the large majority require a medically supervised weight-management program and a psychosocial evaluation (Obesity Surgery, 2020; Surgical Endoscopy, 2022). Requirements vary widely by plan, so verification of individual benefits is essential.

Preoperative evaluation typically includes nutrition and mental-health assessments, laboratory studies (including HbA1c and vitamin/mineral levels), and often an upper endoscopy to screen for hiatal hernia, Barrett's esophagus, or other abnormalities. Smoking cessation is strongly advised (JAMA, 2023; Journal of Laparoendoscopic & Advanced Surgical Techniques, 2020).

Diet advances in stages (clear liquids → full liquids → pureed → soft → solids). Long-term goals include 3 small meals with up to 2 snacks, 80–100 g protein daily, adequate hydration, and lifelong supplementation of multivitamins, vitamin B12, iron, folate, calcium, and vitamin D (JAMA, 2020; Journal of the American College of Cardiology, 2018).

‍

Early walking reduces clot risk. Light activity resumes within days, with progressive return to full activity and exercise by 4–6 weeks. Long-term regular physical activity — including resistance training to preserve muscle — supports weight maintenance (Obesity Surgery, 2026).

Gastric bypass patients traveling from Latin America, the Caribbean or elsewhere should plan to stay in Miami for approximately one week. Pre-operative consultations and nutrition education can be completed virtually, and post-operative visits continue by telehealth with English- and Spanish-speaking staff.